Rectal cancer patient registry
Part of Cancer, Digestive system clinical trials.
This study is a registry that collects information about people with rectal cancer to help doctors learn more about the disease and its treatment. It focuses on patients receiving a certain treatment plan (TNT) or with a specific genetic marker (dMMR/MSI-H), and aims to improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have been diagnosed with rectal cancer that has not spread to distant organs (no distant metastases).
- Your rectal cancer must be either being treated with a specific approach called total neoadjuvant therapy (TNT), or it must be a type called dMMR/MSI-H (which is a special genetic marker) — if it's dMMR/MSI-H, any treatment is allowed.
- You must agree to participate and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at molecular (tumor biology) features of rectal cancer in people receiving standard short-course radiation. Your tissue and/or samples may be used to better understand the cancer and how it responds to treatment.
This study looks at how rectal cancer responds to the usual chemotherapy and radiation given before surgery. It aims to learn if certain molecular features of your tumor can predict how well it responds to treatment.
This study is for people with rectal cancer who have had treatment like radiation or chemo and their tumor has disappeared or nearly disappeared. Instead of surgery right away, doctors will closely monitor the cancer with regular check-ups to make sure it stays gone.
This study follows real-world treatment of locally advanced rectal cancer (cancer that has grown into nearby tissues but hasn't spread to distant organs) in patients who receive chemotherapy and/or radiation before surgery. Researchers track how different treatment approaches work to help improve outcomes.
This trial studies lab “biomarkers” (measurable cancer features) to predict whether rectal cancer will resist chemo-radiation before surgery. The goal is to help doctors better choose treatments and avoid ineffective therapy.
This study looks at how an MRI “score” (mrTRG) matches how well locally advanced rectal cancer shrinks after pre-surgery chemotherapy and radiation. The goal is to use MRI results to better predict treatment response and guide care.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.